Baxter's first-quarter 2022 results showed a 26% increase in revenue to $3.7 billion, driven by the Hillrom acquisition and growth in Medication Delivery and BioPharma Solutions. U.S. GAAP EPS was $0.14, while adjusted EPS reached $0.93. The company is navigating challenges including COVID-19 impacts, geopolitical unrest, and inflationary pressures.
First-quarter revenue increased 26% to $3.7 billion, with a 3% operational growth.
U.S. sales increased 49% on a reported basis and 3% operationally, totaling $1.76 billion.
U.S. GAAP EPS was $0.14, and adjusted EPS was $0.93, a 22% increase.
Hillrom businesses contributed approximately $755 million to first-quarter performance.
Baxter expects full-year 2022 sales growth of 23% to 24% on a reported basis, and adjusted EPS of $4.12 to $4.20. For the second quarter, the company anticipates sales growth of approximately 26% and adjusted EPS of $0.86 to $0.89.
Visualization of income flow from segment revenue to net income